Agios Drops Tebapivat in SCD: Novo Nordisk Raises the Bar

Agios Pharmaceuticals (AGIO) discontinued development of tebapivat in sickle cell disease after Phase 2 results showed the drug did not demonstrate enough differentiation to support continued development. The decision, announced July 21, narrows Agios’ sickle cell pipeline to a single asset and comes as competition in the SCD market intensifies.

The stock closed at $36.28 on July 23, down modestly from its previous close of $36.05. Agios has a market cap of approximately $2.2 billion.

Price update August 2, 2026 (Polygon): AGIO closed at $30.02 on July 31, down 17.3% from the $36.28 reference price in this article. The decline accelerated after Agios’s Q2 earnings report on July 30, where mitapivat revenue beat estimates but the company posted a quarterly net loss and the Nov 1 PDUFA for the SCD sNDA looms with mixed pain-crisis data. See our AGIO Q2 earnings coverage for details.

What tebapivat is and why it fell short

Tebapivat is a pyruvate kinase (PK) activator, part of the same drug class as Agios’ approved drug Pyrukynd (mitapivat). PK activators work by boosting ATP production in red blood cells, which should reduce sickling by improving red cell metabolism and energy.

The Phase 2 trial did not show enough clinical benefit to justify advancing to late-stage development. Agios did not specify which endpoints fell short, but Truist analyst Gregory Renza noted the drug “did not demonstrate the level of differentiation required to support continued development.”

This is not a safety failure. It is an efficacy failure. The drug did its job at the biochemical level but did not translate that into meaningful symptom improvement for patients.

What remains: mitapivat and the November 1 PDUFA

Agios now leans entirely on mitapivat for its sickle cell disease ambitions. The company submitted a supplemental NDA for mitapivat in SCD, and the FDA granted Priority Review with a PDUFA date of November 1, 2026.

The problem: mitapivat’s own Phase 3 RISE UP trial had mixed results. Hemoglobin improvement was statistically significant, but the primary endpoint of reducing sickle cell pain crises was not met. Agios is pursuing accelerated approval based on hemoglobin improvement as a surrogate endpoint, a pathway the FDA accepted after a pre-sNDA meeting in March 2026.

If the FDA approves mitapivat for SCD in November, Agios has its first SCD product on the market. But the mixed data means the commercial story is more complicated than a clean Phase 3 win.

The competitive threat: Novo Nordisk’s etavopivat

The broader risk is competitive. Novo Nordisk’s etavopivat, another PK activator, met both co-primary endpoints in the Phase 3 HIBISCUS trial: a 27% reduction in the annualised rate of vaso-occlusive crises and a hemoglobin response rate of 48.7% (patients achieving >1 g/dL increase at Week 24) versus 7.2% on placebo. That raises the bar for any new entrant. If etavopivat delivers cleaner clinical data than mitapivat, Agios faces a competitor with a stronger efficacy profile in the same drug class.

Beyond PK activators, the SCD market already includes Vertex’s Casgevy (gene therapy) and Bluebird Bio’s Lyfgenia (gene therapy), both approved in late 2023. These are curative-intent one-time treatments for severe disease, while PK activators are chronic oral therapies for the broader SCD population.

What to watch next

The November 1 PDUFA for mitapivat is the next major catalyst. If approved, Agios enters the SCD market with an oral therapy that can be prescribed alongside or instead of the more complex gene therapy options. For a framework on how to think about PDUFA dates and the run-up trade, see our PDUFA date guide. The risk: the mixed pain crisis data could limit the label or trigger an advisory committee.

Agios’ core franchise in thalassemia and pyruvate kinase deficiency remains intact. The SCD opportunity is uncertain, and the market at $36.28 is pricing in that uncertainty.

Source: Agios press release | Reuters